ResearcherThe Cancer Institute HospitalActive in the last 2 years
Takashi Yokokawa
Matched on ORCID iD 0000-0001-9988-128X; OpenAlex author ID A5007566552. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers
Papers 7
- Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. Co-author DOI 10.1002/bcp.70611↗
- Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-026-03201-0↗
- Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-… Co-author DOI 10.1007/s10637-026-01632-0↗
- Factors Affecting Delayed Recovery from Neutropenia in Patients with Pancreatic Cancer Receiving Gemcitabine plus Nab-Paclitaxel. Co-author DOI 10.7150/jca.107359↗
- Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT s… Co-author DOI 10.1002/cncr.35343↗
- Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
- Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy. Co-author DOI 10.1371/journal.pone.0254726↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Naoki Sasahira · 6 shared papers, 2021–2026 · strength 1.23
- Paper Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic … DOI 10.1007/s10637-026-01632-0↗
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Masato Ozaka · 5 shared papers, 2021–2026 · strength 1.07
- Paper Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic … DOI 10.1007/s10637-026-01632-0↗
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Daiki Tsuji · 4 shared papers, 2024–2026 · strength 0.89
- Paper Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic … DOI 10.1007/s10637-026-01632-0↗
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Masahiro Hatori · 4 shared papers, 2024–2026 · strength 0.89
- Paper Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic … DOI 10.1007/s10637-026-01632-0↗
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Kunihiko Itoh · 4 shared papers, 2024–2026 · strength 0.89
- Paper Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic … DOI 10.1007/s10637-026-01632-0↗
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Hiroshi Ishii · 3 shared papers, 2024–2026 · strength 0.63
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Paper Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective… DOI 10.1002/cncr.35343↗
- Ken-ichi Suzuki · 3 shared papers, 2024–2026 · strength 0.63
- Paper Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. DOI 10.1007/s10147-026-03201-0↗
- Paper Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis… DOI 10.1002/bcp.70611↗
- Paper Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective… DOI 10.1002/cncr.35343↗
- Satoko Hori · 2 shared papers, 2021–2025 · strength 0.34
- Paper Factors Affecting Delayed Recovery from Neutropenia in Patients with Pancreatic Cancer Receiving Gemcitabine plus Nab-P… DOI 10.7150/jca.107359↗
- Paper Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination t… DOI 10.1371/journal.pone.0254726↗
- Naoko Yoshida · 1 shared paper, 2025 · strength 0.21
- Aki Otake · 1 shared paper, 2024 · strength 0.16
- Genta Ito · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.